Mnemo Therapeutics has raised €75M in the largest-ever French Series A round, which it will use to develop CAR T-cell immunotherapies for cancer using epigenetic targets.
Mnemo Therapeutics’ mammoth financing, led by Casdin Capital, returning investor Sofinnova Partners, and an undisclosed investor, will allow the startup to accelerate the development of its epigenetic targeting and next-generation cell immunotherapy platform. The round will also help the firm develop its preclinical portfolio in both solid and liquid tumors.
“The goal is to be IND- and phase I-ready by the end of 2023 for at least two projects,” said Alain Maiore, CEO of Mnemo Therapeutics. He added that these initial therapies will target undisclosed cancer antigens that are already known, with trials of treatments targeting the company’s novel epigenetic antigens expected to follow in 2024.
Epigenetics refers to small, reversible modifications to DNA molecules that change the way genes are expressed without altering the genetic code itself. These epigenetic processes are seeing increased interest in the oncology space as they can provide targets for cancer therapies.
The post Huge Series A in France Strengthens European Epigenetic Oncology appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.